Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status

Tharcisse Mpunga, Marie Chantal Umulisa, Vanessa Tenet, Belson Rugwizangoga, Danny A Milner, Cyprien Munyanshongore, Daniëlle A M Heideman, Maaike C G Bleeker, Massimo Tommasino, Silvia Franceschi, Iacopo Baussano, Tarik Gheit, Felix Sayinzoga, Gary M Clifford

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The study aim was to describe human papillomavirus (HPV)-attributable cancer burden in Rwanda, according to anogenital cancer site, HPV type, age and HIV status. Tissue specimens of cervical, vulvar, vaginal, penile and anal cancer diagnosed in 2012-2018 were retrieved from three cancer referral hospitals and tested for high-risk (HR) HPV DNA. Cervical cancer represented the majority of cases (598 of 738), of which 96.0% were HR-HPV positive. HPV-attributable fractions in other cancer sites varied from 53.1% in 81 penile, through 76.7% in 30 vulvar, 83.3% in 24 vaginal, up to 100% in 5 anal cases. HPV16 was the predominant HR-HPV type in cervical cancer (55.0%), followed by HPV18 (16.6%) and HPV45 (13.4%). HPV16 also predominated in other cancer sites (60-80% of HR-HPV-attributable fraction). For cervical cancer, type-specific prevalence varied significantly by histology (higher alpha-9 type prevalence in 509 squamous cell carcinoma vs. higher alpha-7 type prevalence in 80 adenocarcinoma), but not between 501 HIV-negative and 97 HIV-positive cases. With respect to types targeted, and/or cross-protected, by HPV vaccines, HPV16/18 accounted for 73%, HPV31/33/45/52/58 for an additional 22% and other HR-HPV types for 5%, of HPV-attributable cancer burden, with no significant difference by HIV status nor age. These data highlight the preventive potential of the ongoing national HPV vaccination program in Rwanda, and in sub-Saharan Africa as a whole. Importantly for this region, the impact of HIV on the distribution of causal HPV types was relatively minor, confirming type-specific relevance of HPV vaccines, irrespective of HIV status.

Original languageEnglish
Pages (from-to)1514-1522
Number of pages9
JournalInternational Journal of Cancer
Volume146
Issue number6
Early online date7 Jun 2019
DOIs
Publication statusPublished - 15 Mar 2020

Cite this

Mpunga, T., Chantal Umulisa, M., Tenet, V., Rugwizangoga, B., Milner, D. A., Munyanshongore, C., ... Clifford, G. M. (2020). Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status. International Journal of Cancer, 146(6), 1514-1522. https://doi.org/10.1002/ijc.32491